Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.81 |
| ▸ | CDK9 | P50750 | 8/20 | 0.81 |
| ▸ | CDK7 | P50613 | 5/20 | 0.81 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.71 |
| ▸ | JAK2 | O60674 | 4/20 | 0.58 |
| ▸ | CDK4 | P11802 | 9/20 | 0.57 |
| ▸ | AURKA | O14965 | 8/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.57 |
| ▸ | CDK1 | P06493 | 4/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | WEE1 | P30291 | 3/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.55 |
| ▸ | PAK4 | O96013 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.55 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076613 | 0.91 | CDK2 (0.80) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2085358 | 0.90 | CDK2 (1.00) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2087906 | 0.89 | CDK2 (0.75) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL29815786 | 0.87 | CDK4 (0.66) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL18454477 | 0.87 | CDK4 (0.66) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2086730 | 0.86 | GSK3B (0.70) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2075987 | 0.83 | CDK2 (1.00) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2086279 | 0.82 | CDK2 (0.67) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2087388 | 0.82 | CDK2 (0.67) | CDK2CDK9CDK7CCNT1CCNE1 | |
| SCHEMBL2085816 | 0.82 | CDK2 (0.67) | CDK2CDK9CDK7CCNT1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | claimed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | claimed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | claimed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | claimed |
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CDK9 1001/4885CDK7 1077/4885 |
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | CDK2 1/4885CDK9 5/4885CDK7 8/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | CDK2 1/4885CDK9 5/4885CDK7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.